الفهرس 
A CUTE L YMPHOBLASTIC L EUKEMIAOnly 14 pages are availabe for public view
 |  | from | 144 |  |  |
| | | from | 144 | | |
Abstract
Abstract
Background: Elevated serum progranulin (PGRN) levels in some hematological malignancies have been demonstrated. However, limited data regarding its prognostic value in acute lymphoblastic leukemia (ALL) outcome is available.
Methods: Measurement of the PGRN level in serum of 40 adult de novo ALL patients and 20 controls using enzyme-linked immunosorbent assay (ELISA) pre and post induction chemotherapy was performed with comparison.
Results: Serum PGRN level was significantly higher in ALL patients than controls. serum PGRN level is much increased in adult ALL patients pre induction chemotherapy and its level decreases at day 28 evaluation post induction chemotherapy especially in patients with complete remission (CR) and negative minimal residual disease (MRD). Day 28 post induction chemotherapy serum PGRN level showed significant positive correlation with total leukocytic count (P=0.048) and blast count in peripheral blood (P=0.025). High serum PGRN level was not associated with inferior overall survival (OS) and disease-free survival (DFS).
Conclusion: we suggest that the evaluation of plasma PGRN expression pre and post induction chemotherapy may assist in predicting prognosis and remission in ALL patients.